

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

EPOR RABBIT PAB

货号: S219762 产品全名: EPOR 兔多抗 基因符号 EPO-R

UNIPROT ID: P19235 (Gene Accession - NP_000112)

背景: This gene encodes the erythropoietin receptor which is a member of the cytokine receptor family. Upon erythropoietin binding, this receptor activates Jak2 tyrosine kinase which activates different intracellular pathways including: Ras/MAP kinase, phosphatidylinositol 3-kinase and STAT transcription factors. The stimulated erythropoietin receptor appears to have a role in erythroid cell survival. Defects in the erythropoietin receptor may produce erythroleukemia and familial erythrocytosis. Dysregulation of this gene may affect the growth of certain tumors. Alternate splicing results in multiple transcript variants.

抗原: Synthetic peptide of human EPOR

经过测试的应用: ELISA, IHC


推荐稀释比: IHC: 50-200; ELISA: 2000-5000

种属反应性: Rabbit 克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat

成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


研究领域: Signal Transduction, Cardiovascular, Immunology, Stem Cells 储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 219762(EPOR Antibody) at a dilution of 1/40(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 219762(Anti-EPOR Antibody) at dilution 1/40.



The image on the left is immunohistochemistry of paraffinembedded Human brain tissue using 219762(Anti-EPOR Antibody) at a dilution of 1/40.



In comparision with the IHC on the left, the same paraffin-embedded Human brain tissue is first treated with synthetic peptide and then with D260313(Anti-EPOR Antibody) at dilution 1/40.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010